Table 2.
Changes in the treatment efficacy parameters considered in the study.
| Parameters | Total PWE (n = 214) |
PWE on newer AED (n = 110) |
PWE on conventional AED (n = 104) |
p-value between % change of newer and conventional AED groups | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| At enrolment | End of study | % change Median (IQR) |
At enrolment | End of study | % change Median (IQR) |
At enrolment | End of study | % change Median (IQR) |
||
|
QOLIE-10 (Mean ± SD) |
2.38 ± 0.69 | 1.84 ± 0.58 | 20.87 (3.44–36) |
2.42 ± 0.71 | 1.84 ± 0.57 | 19.05 (4.54–36.66) |
2.33 ± 0.67 | 1.85 ± 0.59 | 21.05 (1.42–35.50) |
0.65 |
| p < 0.001 | p < 0.001 | p < 0.001 | ||||||||
|
PSQI Median (IQR) |
4 (2–5) |
2 (1–4) |
30.95 (0–50) |
4 (2–5) |
2 (1–4) |
33.33 (0–55.55) |
3 (2–5) |
2 (1–4) |
10 (0–50) |
0.24 |
| p < 0.001 | p < 0.001 | p < 0.001 | ||||||||
|
LAEP (Mean ± SD) |
31.59 ± 9.95 | 28.21 ± 8.89 | 11.11 (-3.63–23.33) |
32.41 ± 10.50 | 27.91 ± 8.63 | 13.16 (0–25) |
30.72 ± 9.30 | 28.53 ± 9.18 | 8.26 (-11.12–21.65) |
0.09 |
| p < 0.001 | p < 0.001 | p = 0.02 | ||||||||
|
GIQLI (Mean ± SD) |
121.95 ± 21.08 | 130.82 ± 16.99 | −3.54 (-15.57–0.73) |
119.75 ± 21.56 | 130.85 ± 16.74 | −4.34 (-25–0.72) |
124.27 ± 20.41 | 130.78 ± 17.34 | −2.66 (-12.69–0.74) |
0.11 |
| p < 0.001 | p < 0.001 | p < 0.001 | ||||||||
| Seizure frequency per PWE in 6 months duration | 0.82 | 0.36 | 56.09 | 0.68 | 0.27 | 60.29 | 0.98 | 0.46 | 53.06 | 0.35 |
AEDs: Antiepileptic drugs; PWE: Persons with epilepsy; QOLIE-10: Patient weighted Quality of life Index in epilepsy; PSQI: Pittsburgh Sleep Quality Index; GIQLI: Gastrointestinal Quality of life Index; LAEP: Liverpool Adverse effect profile; IQR: Interquartile Range